EPO and myeloproliferative disorder: Furthermore, it has been reported that the JAK2/STAT3 pathway participates in the protective effect of erythropoietin (EPO) in subarachnoid hemorrhage (SAH); also, JAK2 and telomerase have a combination effect in the treatment of myeloproliferative neoplasms (MPNs) [45].